WAVEMAN · COMPANY

INSP · Inspire Medical Systems, Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

INSP

Name: Inspire Medical Systems, Inc. (INSP) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Inspire Medical Systems, Inc.

MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001609550

FORM 144 · 2☆ WATCH

INSIDER NET · 180D

-$233.3K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+13.6%

XBRL, annual

NET MARGIN

15.9%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$233.3K over 180 days

-$57.3K over 90 days

more than 51% of Medical Devices

CONGRESS

no member of Congress has reported trading it

FUNDS

fewer than five institutions report holding it

REVENUE

+13.6% year over year

more than 63% of Medical Devices

MARGIN

15.9% net margin

more than 89% of Medical Devices

BUYBACKS

$175.0M repurchased, FY to 2025-12-31

more than 70% of Medical Devices

SHORT

13.6% of shares outstanding short · 5.0 days to cover · settled 2026-07-31

more than 93% of Medical Devices

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$233.3K across 3 people in 180 days.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -34.3%

-34.3%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $233.3K sold by insiders over 180 days, $61.3K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Inspire Medical Systems, Inc. insiders sold a net $233.3K of stock across 198 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Kelly Jason P

See Remarks

SELL

2026-08-07

963.0

$57.3K

Rondoni John

See Remarks

SELL

2026-05-15

2,641.0

$114.3K

Rondoni John

See Remarks

SELL

2026-05-14

700.0

$30.1K

mcCormick Shawn

Director

SELL

2026-05-08

696.0

$31.5K

Rondoni John

See Remarks

SELL

2026-01-09

109.0

$10.9K

198 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 193 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

JOHN RONDONI

FILED 2026-08-24

$4.0K

JASON P KELLY

FILED 2026-08-07

$57.3K

Clinical pipeline

ClinicalTrials.gov · 9 registered trials, 5 still enrolling or running — a status change here is dated weeks before the press release

Not applicable

5 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Executive pay vs shareholder return · Timothy P. Herbert

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2023

$7.5M

$876.4K

$2.2M

+174%

-1%

2022

$5.7M

$8.4M

$2.1M

+239%

+5%

2021

$1.3M

$10.6M

$1.1M

+210%

+37%

2020

$4.9M

$21.7M

$2.5M

+153%

+33%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$912.0M	$802.8M	$624.8M	$407.9M
GROSS PROFIT	$778.8M	$679.8M	$528.2M	$341.7M
OPERATING INCOME	$51.0M	$36.1M	$-40.3M	$-47.6M
NET INCOME	$145.4M	$53.5M	$-21.2M	$-44.9M
EPS (DILUTED)	4.89	1.75	-0.72	-1.60
OPERATING CASH FLOW	$117.0M	$130.2M	$24.7M	$11.6M
CASH	$104.8M	$150.2M	$185.5M	$441.6M
BUYBACKS	$175.0M	$0	$0	$0

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE